-
1.发明公开公开(公告)号：US20240352500A1
公开(公告)日：2024-10-24
申请号：US18684500
申请日：2022-08-18
发明人： Markus Landthaler , Ulrike Zinnall , Igor Minia
IPC分类号： C12P21/02 , C07K14/505 , C07K14/565 , C07K14/59 , C07K14/62 , C12N9/22 , C12N15/11 , C12N15/90
CPC分类号： C12P21/02 , C07K14/505 , C07K14/565 , C07K14/59 , C07K14/62 , C12N9/22 , C12N15/11 , C12N15/907 , C07K2319/30 , C12N2310/20
摘要： The invention is related to a method for producing a secreted recombinant protein of interest in a cell, wherein the method comprises artificially co-expressing a protein different from the secreted recombinant protein of interest.
-
2.发明公开公开(公告)号：US20240270807A1
公开(公告)日：2024-08-15
申请号：US17922179
申请日：2021-04-28
申请人： GENOPHARM INC. , ABION INC.
发明人： Hae Min JEONG , Chan Gyu LEE , Ji Sun LEE , Jun Young CHOI , Na Young KIM , Yong Jin LEE
CPC分类号： C07K14/565 , A61P35/00 , C07K16/32 , C12N15/85 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/732 , C07K2319/33 , C07K2319/35
摘要： The present invention relates to: a recombinant protein in which an interferon-beta mutein, in which an amino acid residue is substituted, and an antibody binding to a specific antigen are fused together; and a pharmaceutical composition for treating cancer, the composition comprising, as active ingredients, a polynucleotide, an expression vector and a recombinant microorganism, and the recombinant protein. In the recombinant protein, the physical properties of interferon-beta are improved through site-specific mutation, and thus the recombinant protein may have improved biological activity and purification efficiency, and the productivity thereof can be increased.
-
公开(公告)号：US20240228587A9
公开(公告)日：2024-07-11
申请号：US18372942
申请日：2023-09-26
发明人： Chang-Yi Wang , Wen-Jiun Peng , Wei-Ting Kao
IPC分类号： C07K14/745 , C07K14/505 , C07K14/535 , C07K14/56 , C07K14/565 , C07K14/57 , C07K19/00
CPC分类号： C07K14/745 , C07K14/505 , C07K14/535 , C07K14/56 , C07K14/565 , C07K14/57 , C07K19/00 , C12N9/644
摘要： A fusion protein is disclosed. The fusion protein of the invention comprises an Fc fragment of an immunoglobulin G and a bioactive molecule, wherein the Fc is a single chain Fc. The amino acids in the hinge of the Fc is mutated, substituted, or deleted so that the hinge of Fc cannot form disulfide bonds. Methods for producing and using the fusion protein of the invention are also provided.
-
公开(公告)号：US20240189423A1
公开(公告)日：2024-06-13
申请号：US18553447
申请日：2022-03-30
IPC分类号： A61K39/00 , A61K47/68 , A61P35/00 , C07K14/475 , C07K14/48 , C07K14/49 , C07K14/495 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/52 , C07K14/525 , C07K14/53 , C07K14/54 , C07K14/55 , C07K14/56 , C07K14/565 , C07K14/57 , C07K14/575 , C07K14/61 , C07K14/65 , C07K16/28 , C12N5/0781
CPC分类号： A61K39/4644 , A61K39/4612 , A61K39/4633 , A61K47/6851 , A61P35/00 , C07K14/475 , C07K14/48 , C07K14/49 , C07K14/495 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/521 , C07K14/525 , C07K14/53 , C07K14/5403 , C07K14/5406 , C07K14/5409 , C07K14/5412 , C07K14/5418 , C07K14/5425 , C07K14/5431 , C07K14/5434 , C07K14/5437 , C07K14/55 , C07K14/56 , C07K14/565 , C07K14/57 , C07K14/575 , C07K14/61 , C07K14/65 , C07K16/2803 , C07K16/2887 , C12N5/0635 , C07K2317/31 , C07K2319/30 , C12N2510/00
摘要： The present disclosure relates to targeted degradation platform technology. For example, the present disclosure relates to bispecific binding agents for degrading endogenous proteins, whether membrane-associated or soluble, using the lysosome pathway. The disclosure also provides methods useful for producing such agents, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various disorders.
-
公开(公告)号：US20230365703A1
公开(公告)日：2023-11-16
申请号：US18026373
申请日：2021-09-17
发明人： Suqin WANG , Liping SONG
IPC分类号： C07K16/28 , C07K16/30 , C07K14/56 , C07K16/18 , C07K14/565 , C07K14/54 , C07K14/705 , A61P35/00
CPC分类号： C07K16/2887 , C07K16/2803 , C07K16/2863 , C07K16/30 , C07K16/2896 , C07K14/56 , C07K16/2827 , C07K16/303 , C07K16/18 , C07K14/565 , C07K14/5434 , C07K14/5428 , C07K14/5443 , C07K14/70503 , A61P35/00 , C07K2319/30 , C07K2319/33 , A61K38/00
摘要： A bispecific recombinant protein, comprising a first functional binding fragment, a second functional binding fragment, and an Fc region. The first functional binding fragment targeting an antigen of interest of the bispecific recombinant protein comprises an antigen-binding fragment, wherein the C-terminus of the CL domain or the C-terminus of the CH1 domain in the antigen-binding fragment is directly connected to or is connected via a linker to the second functional binding fragment having the functions of immunoregulation and/or metabolic regulation and/or endocrine regulation. The recombinant protein can improve the targeting for the target of the second functional binding fragment of the bispecific recombinant protein and can also reduce toxic side effects caused by the non-target protein containing the second functional binding fragment generated during the preparation process targeting non-target organs, tissues and cells.
-
公开(公告)号：US20230250132A1
公开(公告)日：2023-08-10
申请号：US17990438
申请日：2022-11-18
申请人： UBIPROTEIN, CORP.
发明人： Kyunggon Kim , Kwang-Hyun Baek , Sung-Ryul Bae , Myung-Sun Kim , Hyeonmi Kim , Yeeun Yoo , Lan Li , Jung-Hyun Park , Jin-Ok Kim
IPC分类号： C07K1/107 , C07K14/49 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/535 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/605 , C07K14/61 , C07K14/62 , C07K16/00
CPC分类号： C07K1/1075 , C07K14/49 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/535 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/5759 , C07K14/605 , C07K14/61 , C07K14/62 , C07K16/00 , A61K38/00
摘要： The present invention relates to a method for prolonging half-life of a protein or a (poly)peptide by replacing one or more amino acid residues of the protein. Further, the present invention is about the protein having a prolonged half-life prepared by the method above.
-
公开(公告)号：US20230242576A1
公开(公告)日：2023-08-03
申请号：US17990507
申请日：2022-11-18
申请人： UBIPROTEIN, CORP.
发明人： Kyunggon Kim , Kwang-Hyun Baek , Sung-Ryul Bae , Myung-Sun Kim , Hyeonmi Kim , Yeeun Yoo , Lan Li , Jung-Hyun Park , Jin-Ok Kim
IPC分类号： C07K1/107 , C07K14/49 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/535 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/605 , C07K14/61 , C07K14/62 , C07K16/00
CPC分类号： C07K1/1075 , C07K14/49 , C07K14/50 , C07K14/505 , C07K14/51 , C07K14/535 , C07K14/56 , C07K14/565 , C07K14/575 , C07K14/5759 , C07K14/605 , C07K14/61 , C07K14/62 , C07K16/00 , A61K38/00
摘要： The present invention relates to a method for prolonging half-life of a protein or a (poly)peptide by replacing one or more amino acid residues of the protein. Further, the present invention is about the protein having a prolonged half-life prepared by the method above.
-
公开(公告)号：US11667687B2
公开(公告)日：2023-06-06
申请号：US17696222
申请日：2022-03-16
发明人： Sayantan Mitra , Nicole G. Lapuyade , Hikmat Haizar Assi , Madan M. Paidhungat , Dylan L. Daniel , Erwan Le Scolan , Walter A. Bogdanoff , Na Cai , Hsin Wang , Alexey Yevgenyevich Berezhnoy
IPC分类号： C07K14/56 , C07K14/565 , C07K14/57
CPC分类号： C07K14/56 , C07K14/565 , C07K14/57 , C07K2319/30 , C07K2319/50 , C07K2319/70
摘要： Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.
-
公开(公告)号：US20180162948A1
公开(公告)日：2018-06-14
申请号：US15789828
申请日：2017-10-20
发明人： Sherie L. Morrison
IPC分类号： C07K16/28 , C07K14/565 , A61K38/21 , A61K39/395 , A61K45/06 , C07K14/56 , C07K14/57 , C07K16/30 , A61K39/00 , A61K38/00
CPC分类号： C07K16/2896 , A61K38/00 , A61K38/212 , A61K38/215 , A61K38/217 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K14/56 , C07K14/565 , C07K14/57 , C07K16/30 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/74
摘要： In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CD138 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CD138 antibody attached to an interferon alpha (IFN-α) or to a mutant interferon alpha.
-
公开(公告)号：US09988454B2
公开(公告)日：2018-06-05
申请号：US15159829
申请日：2016-05-20
申请人： Immunwork Inc.
发明人： Tse-Wen Chang , Hsing-Mao Chu , Chien-Jen Lin , Chun-Yu Lin
IPC分类号： A61K47/48 , A61K31/137 , C07K16/10 , C07K16/12 , C07K16/18 , C07K16/28 , C07K17/06 , C07K14/565 , C07K7/08 , C07K14/00 , C07K17/02 , A61K47/65 , A61K47/60 , A61K47/64 , A61K47/68
CPC分类号： C07K16/283 , A61K31/137 , A61K47/60 , A61K47/64 , A61K47/65 , A61K47/6849 , A61K47/6883 , C07K7/08 , C07K14/001 , C07K14/565 , C07K16/1027 , C07K16/1203 , C07K16/18 , C07K16/2839 , C07K16/2881 , C07K17/02 , C07K17/06 , C07K2317/31 , C07K2317/35 , C07K2317/55 , C07K2317/622 , C07K2317/64 , C07K2317/76 , C07K2319/33 , C07K2319/70 , C07K2319/74
摘要： The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
547 条记录 (耗时 0.037 秒)
